Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

Westin Forrestal Princeton | Image: Westin
Value-Based Care Calls for Putting Novel Therapies Closer to Patients

June 19th 2025

Coverage from IVBM Princeton, held May 8, 2025.

Mansi Shah, MD
Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

June 11th 2025

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com
Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

June 7th 2025

IVBM Phoenix logo | Image: AJMC
Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

May 19th 2025

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

May 17th 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Continuing Medical Education
View All
June 26th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
June 26th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
June 26th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
June 26th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
June 26th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
June 26th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies
December 20th 2024

Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

Robert M. Rifkin, MD, FACP
Robert M. Rifkin, MD, FACP, discusses how findings from real-world studies on teclistamab and talquetamab presented at the 66th American Society of Hematology Annual Meeting and Exposition reinforce their efficacy and impact on patient outcomes in relapsed/refractory multiple myeloma while panelists discuss how clinicians should prioritize factors such as patient characteristics and treatment history when selecting the most appropriate bispecific therapy for these patients.
Hans Lee, MD
December 19th 2024

Using MRD, Patient Preference to Optimize Multiple Myeloma Care

Hayden E. Klein
Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.
Don M. Benson, MD, PhD, James Cancer Hospital
December 17th 2024

Unlocking Myeloma Outcomes: The Role of Immunity

Maggie L. Shaw
In part 3 of our interview with hematologist-oncologist Don M. Benson, MD, PhD, The Ohio State University Comprehensive Cancer Center, he addresses the unpredictable nature of multiple myeloma outcomes and their multifactorial nature.
ICYMI: Highlights From IMS 2024
December 17th 2024

ICYMI: Highlights From IMS 2024

Maggie L. Shaw
The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.
Hans Lee, MD
December 10th 2024

How Anti–CD-38 Antibodies Are Changing the Standard of Myeloma Care

Hayden E. Klein
Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.
EHA Highlights thumbnail
December 5th 2024

ICYMI: Highlights From EHA 2024

Maggie L. Shaw
Presentations at the European Hematology Association (EHA) 2024 Congress were encouraging for their data on innovations within the hematology/oncology space that are reshaping treatment outcomes.
Matias Sanchez, MD
December 2nd 2024

Balancing Cutting-Edge Therapies With Cost in Multiple Myeloma Treatment

Skylar Jeremias
Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of cell therapies and bispecific antibodies.
Matias Sanchez, MD
November 29th 2024

Transforming Multiple Myeloma Care With Education and Advanced Therapies

Skylar Jeremias
Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver involvement in managing complex therapies and advises oncologists to confidently integrate advanced treatments.
Guidelines | Image Credit: © momius-stock.adobe.com
November 26th 2024

NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma

Maggie L. Shaw
In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.
Don M. Benson, MD, PhD, James Cancer Hospital
November 22nd 2024

Balancing Life and Myeloma: A Patient-Centered Approach

Maggie L. Shaw
In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Elevating Value in Cancer Care With Innovations, Accessibility, Equity
November 21st 2024

Elevating Value in Cancer Care With Innovations, Accessibility, Equity

Cameron Santoro
Coverage from the IVBM Regional event in Denver, Colorado.
Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com
November 19th 2024

OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

Jordyn Sava
The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Don M. Benson, MD, PhD, James Cancer Hospital
November 15th 2024

Elevating Myeloma Care Amidst Complex Treatment Choices

Maggie L. Shaw
Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
Neon CAR T graphic | Image Credit: © kalpis-stock.adobe.com
November 7th 2024

Eque-Cel CAR T Shows Strong Results for Multiple Myeloma

Maggie L. Shaw
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease progression following standard-of-care therapies that include immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies.
Surbhi Sidana, MD, MBBS
October 24th 2024

MRD: A Game Changer in Multiple Myeloma

Maggie L. Shaw
In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: minimal residual disease (MRD) status.
Screenshot of an interview with Courtney VanHouzen, PharmD
October 15th 2024

Making Cancer Care Easier With Community Bispecific Antibody Programs

Alexandra Gerlach Laura Joszt, MA
Allowing patients to stay in their homes to receive bispecific antibodies can make the whole cancer journey easier, explained Courtney VanHouzen, PharmD, of Cowell Family Cancer Center, Munson Healthcare.
Thomas Jefferson | Image: Thomas Jefferson University
October 13th 2024

Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy

Ryan Flinn
Health disparities word cloud | Image Credit: Colored Lights-stock.adobe.com
October 11th 2024

Delays in Myeloma Oral Therapy Linked to Race, Age

Maggie L. Shaw
Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.
Surbhi Sidana, MD, MBBS, Stanford University
October 2nd 2024

Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care

Maggie L. Shaw
On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant.
IMS Recap
October 1st 2024

IMS 2024 Speakers Look Back on Exciting Myeloma Updates

Cameron Santoro Ashley Gallagher Aislinn Antrim
Speakers at the 2024 International Myeloma Society (IMS) conference share the updates from the myeloma space that they were most excited about this year.
Rahul Banerjee, MD, FACP
September 26th 2024

Evaluating T-Cell Therapies in First-Line Multiple Myeloma Treatment

Cameron Santoro Aislinn Antrim
Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, University of Washington, dissects the limited data on T-cell therapies for multiple myeloma, infectious complications, and access to specialized treatment centers.
Anant Madabhushi, PhD.
September 26th 2024

Creating Equitable AI Models for Multiple Myeloma

Cameron Santoro
Anant Madabhushi, PhD, executive director for the Emory Empathetic AI for Health Institute, proposes AI-based solutions to address health care disparities, emphasizing systemic racism and phenotypic variations.
Rahul Banerjee, MD, FACP.
September 26th 2024

MRD as a New Paradigm in Myeloma Treatment

Cameron Santoro Aislinn Antrim
Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual patient management, including decisions about continuing or stopping treatment.
Multiple myeloma | Image credit: freshidea - stock.adobe.com
September 20th 2024

Varied Types, Levels of Support Needed for Patients With Multiple Myeloma

Julia Bonavitacola
Information on the disease and treatments, assistance with insurance, and transportation are among the types of support needed by patients with multiple myeloma to improve outcomes and overall burden.
Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center
September 17th 2024

Bridging Global Treatment Gaps in Relapsed Multiple Myeloma

Maggie L. Shaw
The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the world, explains Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center.
Clinical trial results | Image Credit: Egor-stock.adobe.com
September 12th 2024

D-VRd Boosts MRD Negativity in Transplant-Eligible Multiple Myeloma

Chris Ryan
The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant.
Leland Metheny, MD, University Hospitals Seidman Cancer Center
August 30th 2024

Triple-Target CAR T Cells: Benefits and Challenges

Maggie L. Shaw
In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.
Leland Metheny, MD, University Hospitals Seidman Cancer Center
August 24th 2024

New CAR T Trial in MM Aims for Triple Receptor Targeting

Maggie L. Shaw
Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) that targets 3 receptors on cancer cells and uses electroporation vs the typical lentiviral vector delivery.
Regeneron logo | Image credit: Casimiro – stock.adobe.com
August 21st 2024

FDA Issues CRL for Linvoseltamab in R/R Multiple Myeloma

Hayden E. Klein
The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.
stem cells | Image Credit: jarun011-stock.adobe.com
August 20th 2024

Second ASCT Extends Survival in Relapsed Multiple Myeloma

Maggie L. Shaw
To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.
<12345678
...
11>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo